X4 Pharmaceuticals’ (XFOR) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $3.00 target price on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $1.50 target price on shares of X4 Pharmaceuticals in a research report on Friday, February 7th.

X4 Pharmaceuticals Stock Performance

Shares of NASDAQ XFOR opened at $0.27 on Wednesday. The company has a 50-day simple moving average of $0.44 and a 200-day simple moving average of $0.53. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. The company has a market cap of $46.78 million, a PE ratio of -2.99 and a beta of 0.39. X4 Pharmaceuticals has a 12 month low of $0.24 and a 12 month high of $1.60.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Tuesday, March 25th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The business had revenue of $1.43 million for the quarter, compared to analysts’ expectations of $1.07 million. On average, equities analysts anticipate that X4 Pharmaceuticals will post -0.68 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Adam S. Mostafa sold 74,773 shares of the company’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $33,647.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Paula Ragan sold 76,473 shares of X4 Pharmaceuticals stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the completion of the transaction, the chief executive officer now owns 1,087,386 shares in the company, valued at $489,323.70. The trade was a 6.57 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 202,663 shares of company stock valued at $91,198. Insiders own 1.62% of the company’s stock.

Institutional Trading of X4 Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Cantor Fitzgerald L. P. acquired a new position in X4 Pharmaceuticals during the fourth quarter valued at approximately $30,000. Verition Fund Management LLC acquired a new position in shares of X4 Pharmaceuticals during the 3rd quarter valued at $30,000. Atria Wealth Solutions Inc. purchased a new stake in X4 Pharmaceuticals during the 4th quarter worth $44,000. Wells Fargo & Company MN increased its holdings in X4 Pharmaceuticals by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 78,518 shares of the company’s stock valued at $58,000 after purchasing an additional 26,763 shares in the last quarter. Finally, Bank of America Corp DE raised its position in X4 Pharmaceuticals by 20.3% in the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after purchasing an additional 22,485 shares during the period. Hedge funds and other institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.